RJH Biosciences - Inspired Design, Effective Transfection

mRNA-Fect & TRAIL Therapy for Lung Cancer! mRNA-Fect (50% offer ends Oct 31) https://lnkd.in/gXJ9NGXn We are thrilled to see our key mRNA transfection reagent, mRNA-Fect, highlighted in our latest peer-reviewed research in Molecular Pharmaceutics (American Chemical Society): "mRNA Delivery with Lipopolymers to Rejuvenate TRAIL Therapy for Lung Cancer Treatment"! While Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) holds immense promise for cancer treatment, its clinical development has been stalled by rapid protein clearance. Researchers addressed this issue using our proprietary mRNA-Fect platform to deliver therapeutic mRNA directly. What mRNA-Fect did for mTRAIL: a. Rapid Transfection: Forms stable 200-400 nm nanoparticles, and ~75% positive transfection-positive lung cancer cells within 24 hours. b. Rejuvenating TRAIL: Stimulates rapid TRAIL secretion, activating caspase-3/-7 and reduces lung cancer cell viability by ~80%. c. In Vivo Efficacy: Successfully mediated expression via intravenous, subcutaneous, and intramuscular routes, effectively suppressing tumor growth in a lung cancer xenograft model without adverse effects. 📖 Full paper https://lnkd.in/g3jMjFb3 Isn’t it time to bring mRNA-Fect into your workflow? 📧 [email protected] 🌐 rjhbiosciences.com Tebubio Amerigo Scientific Prodotti Gianni Biozol GmbH CEDARLANE EC BIOLABS OneSciencePlace Omnicell #LPNP #LNP #Biotech #mRNA #CancerResearch #Oncology #GeneTherapy #Nanomedicine #LungCancer #MolecularPharmaceutics #RJHBiosciences

We are excited to report the compatibility of our leading transfection reagent (mRNA-Fect) for effective delivery of self-amplifying RNA (saRNA). The mRNA-Fect was tested by Tebubio using custom saRNA prepared by their CRO. The data confirm that mRNA-Fect enables robust saRNA transfection with strong, durable transgene expression for over 6 days in HEK-293 cells. Whether you are optimizing saRNA for next-generation RNA therapeutics, vaccine development, or long-duration functional assays, mRNA-Fect provides a simple, reproducible solution. Explore mRNA-Fect: https://lnkd.in/gXJ9NGXn #saRNA #RNAtherapeutics #mRNAFect #GeneTherapeutics #DrugDelivery #TebuBio #RJHBiosciences #HEK293 #VaccineDevelopment

CRISPR-Fect from RJH Biosciences - Inspired Design, Effective Transfection enables robust Cas9 RNP delivery. Here is what that looks like in MDA-MB-231 cells with CRISPR-Fect (https://lnkd.in/gqnkw-r7): delivering GFP-targeting Cas9 RNP resulted in a clear loss of fluorescence signal compared to the control group. The platform also achieved ~56% indel formation while maintaining high cell viability. Whether you are running routine bench screens or scaling up commercial therapeutic pipelines, RJH Biosciences - Inspired Design, Effective Transfection is here to streamline your delivery challenges. #CRISPRfect #GeneKnockout #DrugDelivery #LifeSciences #Innovation #BiomedicalEngineering

Our preclinical data validates a "safety-first" platform that preserves organ health and maintains normal blood chemistry without triggering immune responses. These biocompatible, polymer-based transfection reagents ensure high-efficiency gene modulation across diverse biological models while fully maintaining physiological safety. Full July 2026 newsletter https://lnkd.in/gJ_fVrUf #TransfectionReagents #GeneDelivery #DrugDelivery #InVivo #RNAi #Biocompatible #Biotech #RJHBiosciences #siRNA #mRNA #pDNA #CRISPRRNP #LNP #LPNP #Preclinical

LNP-based delivery is widely used, but it often comes with added complexity in formulation and optimization. At RJH Biosciences, we are exploring a more streamlined approach to nucleic acid delivery. One that focuses on simplicity, consistency, and strong performance across systems. No formulation required. Fewer variables to manage. More reproducible outcomes. In this newsletter, we are sharing comparative data across multiple models, including mRNA delivery, gene silencing, and primary immune cell applications. If your workflows currently rely on LNPs, this may be worth a closer look. Learn more on our website or reach out directly to discuss your application: 🌐 www.rjhbiosciences.com 📧 [email protected] We would be happy to connect and explore how this could fit into your work.

Advancing nucleic acid delivery requires more than a single platform; it requires adaptable technologies that perform across diverse biological systems. At RJH Biosciences, we work with partners to develop and optimize polymer-based transfection solutions for RNA and DNA delivery across cell lines, primary cells, and in vivo models. In our latest Contract Services Spotlight, we highlight recent client collaborations including: • Targeted polymer screening to optimize siRNA delivery • Functional siRNA library screening in human cancer and fibroblast cell models These studies demonstrate how tailored delivery strategies can support discovery workflows and therapeutic development. 📩 Read the full newsletter to learn more about our contract research capabilities. For inquiries about how RJH Biosciences can support your research, contact us at [email protected]